XML 80 R64.htm IDEA: XBRL DOCUMENT v3.23.3
Interests in subsidiaries (Tables)
12 Months Ended
Jun. 30, 2023
Investments accounted for using equity method [abstract]  
Summary of interest in subsidiaries
The consolidated financial statements incorporate the assets, liabilities and results of the following subsidiaries in accordance with the accounting policy described in note 2:
 
         
Ownership interest
 
Name
  
Principal place of business /
Country of incorporation
  
2023
%
   
2022
%
 
       
Kazia Laboratories Pty Ltd
   Australia      100.00     100.00
Kazia Research Pty Ltd
   Australia      100.00     100.00
Kazia Therapeutics Inc.
   United States of America      100.00     100.00
Glioblast Pty Ltd
   Australia      100.00     100.00
*Kazia Therapeutics (Hong Kong) Limited
   Hong Kong      —         100.00
*Kazia Therapeutics (Hong Kong) Limited was formally deregistered and dissolved on 10 March 2023.